Pharma BD Deal Intelligence

Zealand Pharma A/S / OTR Therapeutics Co., Ltd.

2025 · Licensing/Option · $2.5B · Complete

Zealand Pharma and OTR Therapeutics entered a multi-program strategic collaboration and license agreement to discover and develop novel oral small-molecule therapeutics for metabolic diseases. OTR receives an initial upfront payment of USD 20 million, which may increase to USD 30 million under pre-agreed conditions, and is eligible for preclinical, development, regulatory and commercial milestones totalling up to approximately USD 2.5 billion (majority commercial milestones) plus tiered royalties. OTR leads preclinical work; Zealand leads global clinical development, regulatory filings and commercialization.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals